Hidden weight problem: PKU adults face higher obesity risk, scientists investigate why
NCT ID NCT07703020
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This observational study looks at how common overweight and obesity are in adults with phenylketonuria (PKU) and what factors might contribute. Researchers will collect clinical data, lab results, and questionnaire responses on diet, exercise, and mental health from 100 adults at metabolic centers in Switzerland and Austria. The goal is to better understand weight gain in PKU to help design future prevention strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify key risk factors for obesity in adults with PKU, pointing toward better preventive strategies and tailored dietary guidance.
- What could go wrong
- As a small, cross-sectional pilot study, it can only show associations, not causes. Results may not apply to all PKU patients or lead to clear interventions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHENYLKETONURIA (PKU) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lausanne University Hospital
Lausanne, Canton of Vaud, 1011, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New oral drug aims to tame PKU's toxic protein buildup
- Experimental enzyme injection aims to tame PKU's toxic amino acid
- Tiny tablets could make PKU management easier for patients
- New PKU drug JNT-517 moves to Long-Term safety trial
- New pill for PKU shows promise in small teen trial
- 10-Year study to track immune risks of PKU drug